SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists

Pharvaris N.V. (NASDAQ:PHVS)

CH · Delayed Price · Currency is USD
31.91-0.11 (-0.34%)
 
Market Cap2.23B+31.5%
Revenue (ttm)0
Net Income-171.57M-0.6%
EPS-2.70+12.6%
Shares Out69.88M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume753,250
Open32.00
Previous Close32.02
Day's Range31.39 - 32.46
52-Week Range20.65 - 43.25
Betan/a
AnalystsBuy
Price Target60.75(+90.38%)
Earnings DateNov 11, 2026
Insider Score
/ 100
PHVS Insider Score

Pharvaris N.V. has a live Insider Score.

Scored on 0 qualifying trades from 0 insiders in the last 90 days.

Unlock the score

About PHVS

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Address
Grafenauweg 8, Zug, ZH, 6300, CH
Market Cap
2.23 billion
Employees
148
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$19.42M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-0.34%
5 Days
-2.95%
1 Month
-9.65%
6 Months
+16.67%
1 Year
+31.53%

$PHVS stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in PHVS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by PHVS's directors and management

Net Shares Purchased by Insiders−600k−300k02025Q32025Q42026Q12026Q22026Q3

Source: SEC EDGAR (Form 4)

Corporate Lobbying

PHVS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New PHVS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to PHVS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in PHVS

ETFEst. Holding Size
IBBiShares Biotechnology ETF$8.18M
IEFAiShares Core MSCI EAFE ETF$4.28M
SCZiShares MSCI EAFE Small-Cap ETF$2.72M
EWNiShares MSCI Netherlands ETF$1.73M
ONEQFidelity Nasdaq Composite Index ETF$860.45K
COROiShares International Country Rotation Active ETF$412.66K

Estimated from each fund’s disclosed top holdings × AUM

PHVS Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

Members only

The live Insider Score for PHVS is included with Insider Access.

Unlock Insider Score

Bull Case vs Bear Case

AI-generated from PHVS’s recent data — informational, not investment advice

Generating analysis…

Insider Score

Our 0–100 Insider Score and the signals behind it.

Members only

The live Insider Score and its full factor breakdown are included with Insider Access.

Unlock Insider Score

Recent Insider Activity

Buys
0
Sells
16
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.
Company Directory & Stock Ticker Database | InsiderBuying.com